BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...and scientific affairs for infant formula and children’s nutrition at Reckitt Benckiser Group plc (LSE:RB). Agendia...
...outcomes. Robin Sawka, BioCentury Staff Moderna Inc. La Jolla Pharmaceutical Co. Editas Medicine Inc. Veracyte Inc. Merus N.V. Evolve BioSystems Inc. Mindera Corp. AnaptysBio Inc. Agendia N.V. Arcutis...
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...head of the institute's Division of Molecular Carcinogenesis and CSO and co-founder of diagnostics play Agendia N.V....
BioCentury | Jul 13, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

...of the MammaPrint test to identify women who need chemotherapy and those who do not. Agendia N.V....
...cancers (see BioCentury, Sept. 5, 2016 ). Agendia B.V., Amsterdam, the Netherlands Business: Diagnostic Jaime De Leon MammaPrint Agendia N.V. American...
BioCentury | Jul 10, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

...of the MammaPrint test to identify women who need chemotherapy and those who do not. Agendia N.V....
...recurrence, but does not recommend the test for women with HER2-positive or triple-negative breast cancers. Mary Romeo MammaPrint Agendia N.V. American...
BioCentury | Sep 5, 2016
Clinical News

MammaPrint: Phase III data

...recurrence, distant metastasis-free interval was 97.8% without chemotherapy. The trial, which is a collaboration between Agendia...
BioCentury | May 13, 2016
Company News

Management tracks

...June 15. Kehoe was CFO at Kraft Foods Group, now The Kraft Heinz Co. (NASDAQ:KHC). Agendia N.V....
BioCentury | Sep 30, 2015
Company News

Management tracks

...Cancer diagnostics company Agendia N.V. (Amsterdam, the Netherlands) named Mark Straley CEO. Straley was president, anatomical pathology...
BioCentury | Aug 18, 2015
Company News

Management tracks

...Molecular diagnostics play Veracyte Inc. (NASDAQ:VCYT) named Neil Barth CMO. Barth was CMO at Agendia N.V. (Amsterdam...
BioCentury | Mar 25, 2015
Politics & Policy

CMS to emphasize clinical utility of prognostic cancer tests

...in patients with colorectal cancer. The committee also considered breast cancer tests including MammaPrint from Agendia N.V....
BioCentury | Mar 9, 2015
Clinical News

MammaPrint FFPE regulatory update

...FDA granted 510(k) clearance to Agendia’s MammaPrint FFPE test to predict the risk of breast cancer...
...of patient age or HER2 receptor status. Agendia markets MammaPrint Fresh for fresh tumor tissue. Agendia N.V....
Items per page:
1 - 10 of 107
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...and scientific affairs for infant formula and children’s nutrition at Reckitt Benckiser Group plc (LSE:RB). Agendia...
...outcomes. Robin Sawka, BioCentury Staff Moderna Inc. La Jolla Pharmaceutical Co. Editas Medicine Inc. Veracyte Inc. Merus N.V. Evolve BioSystems Inc. Mindera Corp. AnaptysBio Inc. Agendia N.V. Arcutis...
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...head of the institute's Division of Molecular Carcinogenesis and CSO and co-founder of diagnostics play Agendia N.V....
BioCentury | Jul 13, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

...of the MammaPrint test to identify women who need chemotherapy and those who do not. Agendia N.V....
...cancers (see BioCentury, Sept. 5, 2016 ). Agendia B.V., Amsterdam, the Netherlands Business: Diagnostic Jaime De Leon MammaPrint Agendia N.V. American...
BioCentury | Jul 10, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

...of the MammaPrint test to identify women who need chemotherapy and those who do not. Agendia N.V....
...recurrence, but does not recommend the test for women with HER2-positive or triple-negative breast cancers. Mary Romeo MammaPrint Agendia N.V. American...
BioCentury | Sep 5, 2016
Clinical News

MammaPrint: Phase III data

...recurrence, distant metastasis-free interval was 97.8% without chemotherapy. The trial, which is a collaboration between Agendia...
BioCentury | May 13, 2016
Company News

Management tracks

...June 15. Kehoe was CFO at Kraft Foods Group, now The Kraft Heinz Co. (NASDAQ:KHC). Agendia N.V....
BioCentury | Sep 30, 2015
Company News

Management tracks

...Cancer diagnostics company Agendia N.V. (Amsterdam, the Netherlands) named Mark Straley CEO. Straley was president, anatomical pathology...
BioCentury | Aug 18, 2015
Company News

Management tracks

...Molecular diagnostics play Veracyte Inc. (NASDAQ:VCYT) named Neil Barth CMO. Barth was CMO at Agendia N.V. (Amsterdam...
BioCentury | Mar 25, 2015
Politics & Policy

CMS to emphasize clinical utility of prognostic cancer tests

...in patients with colorectal cancer. The committee also considered breast cancer tests including MammaPrint from Agendia N.V....
BioCentury | Mar 9, 2015
Clinical News

MammaPrint FFPE regulatory update

...FDA granted 510(k) clearance to Agendia’s MammaPrint FFPE test to predict the risk of breast cancer...
...of patient age or HER2 receptor status. Agendia markets MammaPrint Fresh for fresh tumor tissue. Agendia N.V....
Items per page:
1 - 10 of 107